| 1671 |
TIGASDO |
MOMETASONE FUROATE 0.1 % W/W |
TOPICAL CREAM |
TUBE |
FOR THE TREATMENT OF INFLAMMATORY AND PRURITIC MANIFESTATION OF PSORIASIS (EXCLUDING WIDESPREAD PLAQUE PSORIASIS) AND ATOPIC DERMATITIS IN ADULT AND CHILDREN AGED 2 YEARS AND OLDER. |
NULL |
LAVI PRODUCTION AND TRADE SOLE CO.,LTD |
SOUTHERN PHARMACEUTICAL JOINT STOCK COMPANY |
VIETNAM |
CERTIFICATE RELEASED |
05 I 5936/25 |
19-MAY-2025 |
18-MAY-2030 |
View |
| 1672 |
LUCISEMAG 14 MG |
SEMAGLUTIDE 14 MG |
TABLET |
BOTTLE |
AS AN ADJUNCT TO DIET AND EXCERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETE MELLITUS |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
08 L 1183/24 |
22-AUG-2024 |
21-AUG-2027 |
View |
| 1673 |
LUCISEMAG 3 MG |
SEMAGLUTIDE 3 MG |
TABLET |
BOTTLE |
AS AN ADJUNCT TO DIET AND EXCERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETE MELLITUS |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
08 L 1182/24 |
22-AUG-2024 |
21-AUG-2027 |
View |
| 1674 |
LUCISEMAG 7 MG |
SEMAGLUTIDE 7 MG |
TABLET |
BOTTLE |
AS AN ADJUNCT TO DIET AND EXCERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETE MELLITUS |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
08 L 1186/24 |
22-AUG-2024 |
21-AUG-2027 |
View |
| 1675 |
LUCIABE |
ABEMACICLIB 50 MG |
TABLET |
BOTTLE |
FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR POSTIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR NEGATIVE, NODE POSITIVE, EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE. |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
03 L 1324/25 |
28-MAR-2025 |
27-MAR-2030 |
View |
| 1676 |
LUCIABRO |
ABROCITINIB 100 MG |
TABLET |
BOTTLE |
TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE TO SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT SDEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, INCLUDING BIOLOGICS OR WHEN USE OF THOSE THERAPIES IS INADVISABLE |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
02 L 1061/24 |
20-FEB-2024 |
19-FEB-2027 |
View |
| 1677 |
LUCIACAL |
ACALABRUTINIB 100 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY, CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
03 L 1314/25 |
07-APR-2025 |
06-APR-2030 |
View |
| 1678 |
LUCIADA |
ADAGRASIB 200 MG |
TABLET |
BOTTLE |
FORT HE TREAMENT OF ADULT PATIENTS WITH KRAS G12C MUTATED LOCALLY ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
02 L 1070/24 |
14-MAR-2023 |
13-MAR-2027 |
View |
| 1679 |
LUCIAFA |
AFATINIB 40 MG |
TABLET |
BOTTLE |
FIRST - LINE TREATMENT OF PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON RESISTANT EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
07 L 1142/24 |
12-JUL-2024 |
11-JUL-2027 |
View |
| 1680 |
LUCIALE |
ALECTINIB 150 MG |
CAPSULE |
BOTTLE |
TREATMENT OF PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE POSITIVE |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
06 L 1127/24 |
21-JUN-2024 |
20 JUN 2027 |
View |
